CASI PHARMACEUTICALS INC (CASI) Stock Price, Quote, News and Overview
NASDAQ:CASI - Nasdaq - KYG1933S1012 - Common Stock - Currency: USD
CASI Quote, Performance and Key Statistics
NASDAQ:CASI (2/21/2025, 8:05:15 PM)
2.45
-0.01 (-0.41%)
The current stock price of CASI is 2.45 USD. In the past month the price decreased by -5.04%. In the past year, price decreased by -55.86%.
CASI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CASI
Company Profile
CASI Pharmaceuticals, Inc. engages in developing and commercializing therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 176 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Company Info
CASI PHARMACEUTICALS INC
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District
Beijing BEIJING 20850 CN
CEO: Wei-Wu He
Employees: 176
Company Website: http://www.casipharmaceuticals.com/
Investor Relations: https://www.casipharmaceuticals.com/investor-relations/
Phone: 861065618789
CASI PHARMACEUTICALS INC / CASI FAQ
What is the stock price of CASI PHARMACEUTICALS INC today?
The current stock price of CASI is 2.45 USD. The price decreased by -0.41% in the last trading session.
What is the ticker symbol for CASI PHARMACEUTICALS INC stock?
The exchange symbol of CASI PHARMACEUTICALS INC is CASI and it is listed on the Nasdaq exchange.
On which exchange is CASI stock listed?
CASI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CASI PHARMACEUTICALS INC stock?
7 analysts have analysed CASI and the average price target is 6.12 USD. This implies a price increase of 149.8% is expected in the next year compared to the current price of 2.45. Check the CASI PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CASI PHARMACEUTICALS INC worth?
CASI PHARMACEUTICALS INC (CASI) has a market capitalization of 32.83M USD. This makes CASI a Nano Cap stock.
How many employees does CASI PHARMACEUTICALS INC have?
CASI PHARMACEUTICALS INC (CASI) currently has 176 employees.
What are the support and resistance levels for CASI PHARMACEUTICALS INC (CASI) stock?
CASI PHARMACEUTICALS INC (CASI) has a support level at 2.45 and a resistance level at 2.49. Check the full technical report for a detailed analysis of CASI support and resistance levels.
Is CASI PHARMACEUTICALS INC (CASI) expected to grow?
The Revenue of CASI PHARMACEUTICALS INC (CASI) is expected to decline by -45.64% in the next year. Check the estimates tab for more information on the CASI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CASI PHARMACEUTICALS INC (CASI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CASI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CASI, evaluating the profitability, health, valuation and growth aspects
- CASI PHARMACEUTICALS INC (CASI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CASI PHARMACEUTICALS INC (CASI) Sales and EPS estimates to see what analysts future expectations are.
- CASI PHARMACEUTICALS INC (CASI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CASI PHARMACEUTICALS INC (CASI) Insider and Institutional Ownership to learn about the owners and their transactions.
- CASI PHARMACEUTICALS INC (CASI) Stock Chart to make your own analysis
- CASI PHARMACEUTICALS INC (CASI) Latest news and press-releases to stay up to date.
Does CASI PHARMACEUTICALS INC (CASI) stock pay dividends?
CASI does not pay a dividend.
What is the Price/Earnings (PE) ratio of CASI PHARMACEUTICALS INC (CASI)?
CASI PHARMACEUTICALS INC (CASI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.26).
What is the Short Interest ratio of CASI PHARMACEUTICALS INC (CASI) stock?
The outstanding short interest for CASI PHARMACEUTICALS INC (CASI) is 0.65% of its float. Check the ownership tab for more information on the CASI short interest.
CASI Technical Analysis
CASI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CASI. CASI may be in some trouble as it scores bad on both profitability and health.
CASI Financial Highlights
Over the last trailing twelve months CASI reported a non-GAAP Earnings per Share(EPS) of -2.26. The EPS increased by 34.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.83% | ||
| ROE | -111.6% | ||
| Debt/Equity | 0.78 |
CASI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CASI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -29.27% and a revenue growth -45.64% for CASI